| pubmed-article:12080377 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12080377 | lifeskim:mentions | umls-concept:C0001483 | lld:lifeskim |
| pubmed-article:12080377 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:12080377 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:12080377 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:12080377 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:12080377 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:12080377 | pubmed:dateCreated | 2002-6-24 | lld:pubmed |
| pubmed-article:12080377 | pubmed:abstractText | Mutations and aberrant expression of the p53 tumor suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the wild-type (wt) p53 protein and presented by major histocompatibility complex (MHC) molecules for T lymphocyte recognition are believed to serve as universal tumor-associated antigens for cancer immunotherapy. We studied the immunogeneicity of a recombinant replication-defective adenoviral vector encoding human full-length wt p53 (rAd/hup53) in human leukocyte antigen (HLA)-A2K(b)-transgenic (Tg) mice and man. The generation of p53 epitope-specific cytotoxic T lymphocytes (CTLs) in p53-proficient and p53-deficient A2K(b)-Tg mice was affected by self-tolerance and a selective inability of rAd/hup53 to induce p53.264-272 peptide-reactive effector cells. To extend this study into a pilot clinical trial, six advanced-stage cancer patients received sequential injections of rAd/hup53. The treatment was well tolerated. To date, no evidence for objective tumor responses was observed. An amplification of humoral and cellular anti-adenoviral immune responses was demonstrated in all patients following rAd/hup53 vaccination. However, p53-reactive antibodies and HLA-A*0201 (A2.1)-restricted CTLs specific for wt p53 epitopes were not generated. Tailoring p53-based cancer immunotherapy thus requires the interference with p53-specific self-tolerance and the induction of the entire repertoire of p53-reactive T lymphocytes. | lld:pubmed |
| pubmed-article:12080377 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12080377 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12080377 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12080377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12080377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12080377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12080377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12080377 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12080377 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12080377 | pubmed:issn | 0969-7128 | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:NeumannMM | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:SchulerMM | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:HuberCC | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:HerrWW | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:WestreichLL | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:WölfelTT | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:TheobaldMM | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:KuballJJ | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:Antunes... | lld:pubmed |
| pubmed-article:12080377 | pubmed:author | pubmed-author:Obenauer-Kutn... | lld:pubmed |
| pubmed-article:12080377 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12080377 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:12080377 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12080377 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12080377 | pubmed:pagination | 833-43 | lld:pubmed |
| pubmed-article:12080377 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:meshHeading | pubmed-meshheading:12080377... | lld:pubmed |
| pubmed-article:12080377 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12080377 | pubmed:articleTitle | Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. | lld:pubmed |
| pubmed-article:12080377 | pubmed:affiliation | Department of Hematology and Oncology, Johannes Gutenberg-University, Mainz, Germany. | lld:pubmed |
| pubmed-article:12080377 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12080377 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12080377 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12080377 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12080377 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12080377 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12080377 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12080377 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12080377 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12080377 | lld:pubmed |
